Tryvio (Aprocitentan) – Hypertension | HongKong DengYue Medicine

Tryvio Application Scope

Tryvio™ (aprocitentan) is a once-daily oral endothelin receptor antagonist approved by the FDA for use alongside other antihypertensive medications to treat adults with resistant hypertension not adequately controlled by existing therapies.

Characteristics

• Ingredients: Aprocitentan

• Properties: Dual endothelin receptor antagonist (ERA) targeting both ETA and ETB receptors to reduce blood pressure in patients with resistant hypertension

• Packaging Specification: 12.5 mg film-coated tablets; supplied in blister packs of 10 or bottles of 30 tablets

• Storage:

  • Store at 20–25°C (68–77°F); excursions permitted between 15–30°C (59–86°F)

  • Keep in original packaging with desiccant; protect from light and moisture

• Expiry Date: ​Refer to the expiration date printed on the packaging

• Executive Standard: ​FDA-approved labeling and prescribing information

• Approval Number: NDA 215999

• Date of Revision: ​April 2025

• Manufacturer: Idorsia Pharmaceuticals US Inc.

Guidelines for the Use of Tryvio

• Dosage and Administration:

  • The recommended dosage is 12.5 mg orally once daily.
  • Tablets should be swallowed whole and can be taken with or without food.
  • If a dose is missed, skip the missed dose and take the next dose at the regular time
  • Do not take two doses on the same day

• Adverse Reactions:

  • Common adverse reactions (≥5%) include edema/fluid retention and anemia.

  • Hypersensitivity reactions such as rash, erythema, and allergic edema have been reported

 

• Contraindications: Contraindicated in pregnancy and patients with known hypersensitivity to aprocitentan or any of its excipients

• Precautions:

  • Monitor for signs of fluid retention, especially in patients with renal impairment or heart failure.

  • Liver function tests should be obtained before initiation and repeated during treatment as clinically indicated.

  • Use effective contraception in females of reproductive potential during treatment and for one month after discontinuation.

Interactions

• Drug Interactions: No specific drug interaction studies have been conducted. Based on its metabolism, interactions with strong CYP3A4 inhibitors or inducers are considered unlikely.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.